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Abstract: Phenolic compounds are among the most investigated herbal remedies, as is especially the
case for resveratrol. Many reports have shown its anti-aging properties and the ability to reduce
obesity and diabetes induced by high-fat diet in mice. However, such beneficial effects hardly
translate from animal models to humans. The scientific community has therefore tested whether
other plant phenolic compounds may surpass the effects of resveratrol. In this regard, it has been
reported that piceatannol reproduces in rodents the anti-obesity actions of its parent polyphenol.
However, the capacity of piceatannol to inhibit adipocyte differentiation in humans has not been
characterized so far. Here, we investigated whether piceatannol was antiadipogenic and antilipogenic
in human preadipocytes. Human mesenchymal stem cells (hMSC), isolated from adipose tissues of
lean and obese individuals, were differentiated into mature adipocytes with or without piceatannol,
and their functions were explored. Fifty µM of piceatannol deeply limited synthesis/accumulation
of lipids in both murine and hMSC-derived adipocytes. Interestingly, this phenomenon occurred
irrespective of being added at the earlier or later stages of adipocyte differentiation. Moreover,
piceatannol lowered glucose transport into adipocytes and decreased the expression of key elements
of the lipogenic pathway (PPARγ, FAS, and GLUT4). Thus, the confirmation of the antiadipogenic
properties of piceatanol in vitro warrants the realization of clinical studies for the application of this
compound in the treatment of the metabolic complications associated with obesity.
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1. Introduction
Obesity and its complications have reached epidemic proportions, being considered as serious
public health threats worldwide. Considering the limited results of classical pharmacological
approaches for the treatment of obesity, phytochemicals have emerged as a novel alternative to
mitigate its morbidity. Natural phenolic compounds, such as resveratrol, are among the most studied
anti-obesity phytochemicals since 2006, when it was reported that resveratrol had anti-aging properties
and was able to reduce obesity and diabetes induced by high-fat diet in mice [1]. Those beneficial
effects were partially confirmed in other animal studies as well as in humans (reviewed in [2]).
Nevertheless, recent meta-analyses converged to indicate that the effects were limited and that there
is still insufficient evidence to support the use of resveratrol supplements for the management of
obesity in humans [3,4]. Even the extreme term “resveratrol fiasco” has been coined to reflect this
scientific deception [5]. As a consequence, the research for resveratrol-like molecules with higher
bioavailability and equivalent, or even greater, anti-obesity properties has been the object of intense
efforts recently [6].
Piceatannol (trans-3,4,3′,5′-tetrahydroxystilbene) is a natural phenolic stilbenoid chemically
similar to resveratrol but having an extra hydroxyl group at the 3′ position. It is present in various
kinds of food such as berries, passion fruit seeds, peanuts, grapes, wine, and white tea [7]. Although
piceatannol has been the subject of far less numerous studies than resveratrol [8], its effects on
limiting hypercholesterolemia, atherosclerosis, arrhythmia, and angiogenesis, which are common
complications of obesity, have already been described [9]. Regarding adipose tissue physiopathology,
it has been repeatedly shown that piceatannol inhibits adipogenesis in 3T3-L1 cells, a murine model of
preadipocytes [10–12]. Similar antiadipogenic effect has been observed on a stable cell line derived from
human liposarcoma [13]. Although all those cell lines are useful models for the study of differentiation
into adipocytes, one should keep in mind that their metabolism (and mainly their lipid handling)
might deviate from the physiological metabolism of mature adipocytes found in the adipose tissue [14].
This prompted us to verify whether such potential antiadipogenic action was effective in cells isolated
from human non-pathological fat depots.
In this study, we used human adipocytes derived from adipose mesenchymal stem cells (hMSC)
to investigate the effect of piceatannol on the adipogenic process and the metabolic status of the
adipocytes. Our results confirm that previous observations of the antiadipogenic properties of
piceatannol in preadipocyte lineages can be extrapolated to human adipocytes.
2. Results
2.1. Piceatannol Impairs Lipid Accumulation and Inhibits Lipogenesis in Mouse Adipocytes
Post-confluent 3T3-L1 preadipocytes were treated for one week with piceatannol during the
differentiation process. 50 µM piceatannol produced a 65% reduction of the neutral lipid content
in mature adipocytes (Figure 1A,B), which account for more than 90% of the lipids in this in vitro
model [15]. This preliminary experiment confirmed previous observations indicating that piceatannol
is as antiadipogenic as other phenolic compounds when tested in mouse preadipocytes [10–12].
To further extend our verification of the inhibitory effect of this natural molecule on lipid accumulation,
we tested whether piceatannol and its parent polyphenol, resveratrol, were able to limit the
incorporation of radiolabelled glucose into lipids in mature mouse adipocytes. For this, mouse
adipocytes were incubated with 0.1 mM [3H]-glucose and a 100 µM dose of each polyphenol for 120
min. The incorporation of radiolabelled glucose into newly synthesized lipids was more reduced by
piceatannol than by resveratrol (Figure 2) in a relatively short-term manner. Thus, we obtained a clear
confirmation of the capacity of piceatannol to rapidly inhibit de novo lipogenesis in mouse adipocytes.
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Figure 1. Influence of piceatannol on lipid accumulation in 3T3-L1 derived adipocytes. (A) Oil Red O
staining of the mature adipocytes cultured in multi-well plates after differentiation without (control)
or with 50 µM piceatannol. (B) Quantitative analysis of neutral lipid content. Mean ± SEM of six
determinations. Different from control at * p < 0.05 by Student’s t-test.
Figure 2. Short-term inhibition by piceatannol and resveratrol of the incorporation of glucose into
intracellular lipids in mouse adipocytes. Radiolabelled glucose was incubated for 2 h at 37 ◦C with
freshly prepared mouse adipocytes in the absence (control, black column) or the presence of 100 µM
polyphenol, then radiolabelled lipids were extracted and counted. Glucose incorporation into lipids was
expressed in units relative to the maximal lipogenic effect of insulin. Mean± SEM of 14 determinations.
*** p < 0.001 for the differences between the control, resveratrol, and piceatannol treated groups by
one-way ANOVA and Dunnett’s post-hoc test.
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2.2. Piceatannol Impairs Adipogenesis in Human Preadipocytes
First, we sought to rule out a cytotoxic effect of piceatannol and treated hMSC lines once
differentiated into adipocytes with piceatannol-supplemented medium for 48 h. No noticeable effect
on cell viability was observed in the assayed range (0–50 µM) of piceatannol (not shown). Thereafter,
we verified whether the inter-individual variability observed in the human donors, at least regarding
their body mass index (BMI), was recapitulated in hMSC-derived adipocytes. To this end, different
hMSC lines were established from five different donors, and the lipid accumulation obtained in
hMSC-derived adipocytes was measured with the lipophilic stain Nile Red. This easy-to-use marker
of the ability of hMSC to differentiate into adipocytes indicated that such in vitro capability was
negatively associated with the BMI of the donor. A strongly impaired differentiation of hMSCs into
adipocytes was observed as donor’s BMI increased, probably reflecting an exhausted pool of hMSC
in the adipose tissue of the obese donors (Figure 3A). This comparative approach showed that both
MSC11 and MSC16 cell lines had similar very low levels of lipid accumulation and prompted us to
exclude MSC11 from further studies.
Figure 3. Influence of piceatannol on lipid accumulation in hMSC-derived adipocytes. hMSC obtained
from five individuals anonymously renamed MSC 9, 11, 15, 16, and 19 were differentiated into
adipocytes. (A) Relationship between body mass index of donor and lipid accumulation per well.
Each point on the Y-axis is the mean of quadruplicates. Significant coefficient of linear regression
is indicated. (B) Effect of 50 µM piceatannol on lipid accumulation in four hMSC lines expressed
as percentage of optimal adipogenic condition in the presence of vehicle (DMSO, dark columns).
Each percentage is the mean ± SEM of eight replicates. Different from vehicle at * p < 0.05 by
Student’s t-test.
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We then investigated the effect of piceatannol on the process that drives hMSC to accumulate
lipids, hereafter called adipocyte differentiation or adipogenesis. During this experiment, four lines of
hMSC were treated with the standard differentiation cocktail supplemented with either 0 or 50 µM
piceatannol for seven days. Subsequent lipophilic staining with Nile Red showed that piceatannol
produced a reduction of lipid-containing cells in all the hMSC lines differentiating into adipocytes,
when compared to their respective untreated control (Figure 3B). The inhibitions of 80%, 38%, 47% and
26% of lipid storage in each cell line indicated that the anti-adipogenic properties of the resveratrol
derivative were effective in human cells.
In another set of experiments, mature (eight days post-differentiation) hMSC-adipocytes were
treated with either 0 or 50 µM piceatannol for seven additional days, and intracellular lipids were
determined in two lines. Again, a reduction was observed in piceatannol-treated cells, though less
pronounced than when cells of the same donors were treated during the differentiation process as
above described (Figure 4A). Briefly, the reduction in lipid accumulation was approximately of 50%
when treating the cells during all the adipogenic process, while it was ~15% when piceatannol was
applied to already differentiated adipocytes (Figure 4B). Based on our observations, it can be deduced
that piceatannol impairs adipogenesis in human adipocytes in a maturation-dependent fashion.
Figure 4. Influence of piceatannol on lipid accumulation during the early and late phase of in vitro
adipogenesis. (A) Neutral lipid content in control (black column) or hMSC treated by medium
supplemented with 50 µM piceatannol before (pre-differentiation, white column) of after induction of
adipogenesis (post-differentiation, shaded column). Each column is the mean ± SEM of quadruplicates
for the indicated hMSC lines. ** p < 0.01 for the differences between the control and the pre-
and post-differentiation treatments by one-way ANOVA and Dunnett’s post-hoc test. (B) Picture
of a multi-well culture plate with lipid staining of the line hMSC 9 after control and pre- and
post-differentiation treatment with 50 µM piceatannol.
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To illustrate the overall antiadipogenic effects of piceatannol we pooled the delipidating effects
obtained in the 4 hMSC lines. Figure 5 shows an ~60% average reduction of cellular lipid content when
hMSCs where differentiated into adipocytes in the presence of 50 µM piceatannol.
Figure 5. Inhibition by piceatannol of lipid accumulation in human adipocytes. Each column represents
the mean± SEM of a total of 48 determinations made on a total of four hMSC lines. Difference between
50 µM piceatannol and control condition (DMSO vehicle) at * p < 0.05 by Student’s t-test.
2.3. Piceatannol Induces Desensitization to Insulin Activation of Glucose Uptake and Down-Regulates
Lipogenic Enzymes in Human Adipocytes
Glucose uptake is the first step of glucose utilization and its inhibition may lead to impaired
de novo lipogenesis (DNL). We therefore, examined the effect of piceatannol on basal and
insulin-stimulated glucose transport activity in mature hMSC-adipocytes. Insulin increased
[3H]-deoxyglucose uptake compared to baseline. Such stimulation was significant in at least three of
the four lines tested (Figure 6A). This insulin action was hampered when adipocytes were treated with
50 µM piceatannol during their differentiation process (Figure 6B). In addition, the piceatannol also
reduced basal glucose uptake in two of the four lines studied: MSC9 and MSC16. Although the latter
was apparently insensitive to insulin (not so unexpectedly since obtained from a donor with BMI > 40),
it can be assessed that piceatannol was altering either basal or stimulated glucose transport in all the
lines studied.
Thus, supplementation with piceatannol blunted any increment of glucose transport into the cells
under adipogenic culture conditions, ultimately depriving the adipogenic enzymes of the building
blocks necessary to produce fatty acids and accumulate triglycerides. Consistent with these results,
piceatannol-treated hMSC-adipocytes showed lower mRNA levels of the adipogenic regulators PPARγ
and FAS (Figure 7). Moreover, the expression of glucose transporter GLUT4, which emerges during
adipogenesis, was down-regulated by the polyphenol when compared to non-treated counterparts
(Figure 7).
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Figure 6. Effect of piceatannol on hexose uptake by differentiated hMSC-adipocytes. (A) Stimulation of
[3H]-deoxyglucose uptake by 500 nM insulin in four hMSC lines. The basal hexose uptake determined
under baseline conditions (control, black columns) was increased by insulin (Ins, open columns) in
three of the four lines. Different from respective control at * p < 0.05 by Student’s t-test. (B) Impairment
by piceatannol treatment (Pic) during adipocyte differentiation of the hexose uptake stimulation by
insulin. There was no difference between Pic and Pic + Ins conditions. Each column is the mean ± SEM
of six replicates.
Figure 7. Effect of piceatannol on gene expression of major markers of adipocyte differentiation.
The mRNA abundance is expressed for control, pre- and post-differentiation treatment with 50 µM
piceatannol, as relative units. Each column corresponding to the indicated gene is the mean ± SEM
of four hMSC lines. * p < 0.05 and ** p < 0.01 for the differences between the control the pre- and
post-differentiation treatments by one-way ANOVA and Dunnett’s post-hoc test.
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Such impairment by piceatannol of various steps of the lipogenic pathway, observed in adipocytes
derived from human adipose, totally fits with previous observations made on mouse adipocytes.
Moreover, we also observed that the expression of adiponectin, an adipokine specifically produced
by insulin-sensitive adipocytes, was dramatically reduced by piceatannol treatment (not shown),
indicating that, alongside the lipogenic pathway, many other aspects of the adipogenic differentiation
process were altered.
2.4. Piceatannol Dose-Dependently Limits Hydrogen Peroxide Detection in Human Adipose Tissue
Preparations
Insulin stimulation increases hydrogen peroxide production by NADPH oxidase in
adipocytes [16]. In turn, hydrogen peroxide may mimic insulin activation of the glucose transport and
lipogenic activities [17]. Consequently, we next tested whether the polyphenol could modify the fate of
hydrogen peroxide release in preparations of human adipose tissue. Piceatannol reproduced in human
subcutaneous adipose tissue (AT) the known antioxidant properties of stilbenoids, since it inhibited
almost totally the spontaneous release of hydrogen peroxide (Figure 8). Although piceatannol was
ineffective between 10−8 and 10−5 M, it clearly lowered the detected levels of hydrogen peroxide
release when present at 10−4 or 10−3 M in the AT homogenates for 30 min.
Figure 8. Inhibition of hydrogen peroxide detection by piceatannol in human adipose tissue (AT)
preparations. Mean ± SEM of five individuals.
3. Discussion
Our in vitro study accumulated evidences of diverse antiadipogenic effects of piceatannol.
First, as an antioxidant, it rapidly altered in AT the fate of hydrogen peroxide, an agent known
to activate glucose transport and lipogenesis in adipocytes [17,18]. Second, piceatannol rapidly
abolished the glucose incorporation into lipids in mouse adipocytes, as already reported for two related
stilbenoids—resveratrol and pterostilbene [19]. Third, when present during hMSC differentiation,
it clearly prevented lipid accumulation, impaired insulin stimulation of glucose uptake and limited
the expression of important genes in the adipogenic programme.
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The dose of 50 µM piceatannol used for chronic treatments in this study was indicated as optimal
in the pioneering work of Kwon and coworkers [10], showing that at this dose, piceatannol clearly
inhibited adipogenesis in murine preadipocytes. However, this dose might not be the lower limit
of piceatannol effectiveness regarding lipid deposition. We have observed in a recent study that the
inhibition of triglyceride content in 3T3-L1 differentiating preadipocytes was detectable with 25 µM of
the molecule, while 10 µM was clearly insufficient to alter adipogenesis [11]. A major limitation of
our study is that it cannot be assessed whether 50 µM piceatannol is a concentration reachable in the
adipose depots after nutritional intervention. The plasma values reported during pharmacokinetic
experiments in animal models led to consider that the upper limit for circulating piceatannol could
be set at approximately 10 µM [20]. Hence, the clinical relevance of piceatannol supplementation in
mitigating obesity must be evaluated with caution, although piceatannol did appear to be more active
than resveratrol at micromolar doses in reducing lipid deposition in mouse adipocytes.
Several clinical trials with this natural polyphenol have been already performed while other are
under completion. Among these recent controlled supplementations, the work reported by Kitada
and colleagues [21] indicated that oral piceatannol administration (purified from passion fruit seed
extract) does not promote weight loss, but improves several complications of obesity, such as elevated
insulin levels, high blood pressure, and elevated heart rate in men with BMI ≥ 25. A protective
effect of piceatannol on 3T3-L1 adipocytes exposed to the proinflammatory molecule TNFα has also
been described [22]. In contrast, our in vitro data indicate that piceatannol affects negatively both
basal and insulin-stimulated glucose transport in hMSC differentiated into adipocytes. Even when
there was practically an absolute resistance to insulin action in cells derived from one of the donors,
piceatannol treatment further hampered glucose uptake. Such inhibition of insulin responsiveness
induced by previous exposure of human adipose cells to piceatannol appears however in agreement
with its inhibitory role for the tyrosine kinase activity of the insulin receptor in 3T3-L1 models [10],
similarly to resveratrol [23]. Since during this study we could not obtain freshly prepared adipocytes
from subcutaneous AT of donors, it was not possible to directly evidence whether piceatannol can
rapidly inhibit lipogenic activity of human adipocytes ex vivo. Nevertheless, as we already reported
that hydrogen peroxide mimics several insulin actions in human adipocytes [18], we posit that the
inhibitory influence of piceatannol on the fate of hydrogen peroxide in the AT could be mirrored by
an inhibition of adipocyte lipogenic activity.
Piceatannol was recently proposed to inhibit glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), the enzyme catalyzing the 6th step of glycolysis, and known to exert many other functions.
It is the piceatannol capacity to interact with the highly reactive cysteine residue in the enzyme’s active
site that prompted the authors to propose a redox-sensitive inhibition [24]. However, this GAPDH
enzyme is not the same as the glycerol-3-phosphate dehydrogenase (GPDH), which catalyzes the
reversible conversion between dihydroxyacetone phosphate and glycerol 3-phosphate. This GPDH
is an important step in the lipogenic pathway located at the crossroad between carbohydrate and
lipid metabolism. As is the case with GAPDH, one isoform of GPDH is located in the cytoplasm
coupled to a NADH/NAD+ exchange, we hypothesize that GAPDH might be potentially affected by
piceatannol, too. Such putative mechanism may reconcile the rapid and long-lasting inhibitory effects
of piceatannol on lipid storage in fat cells, since the observed down-regulation of GLUT4, which fits
with long-lasting anti-adipogenic action, cannot on its own explain the rapid impairment of glucose
incorporation into lipids observed within two hours in mouse adipocytes.
Regarding piceatannol’s capacity to lower the detection of hydrogen peroxide in AT preparations,
it should be noted that the antioxidant effects of piceatannol occurred at concentrations similar
than that required for the antilipogenic effect but higher than that limiting adipogenesis. This does
not indicate whether the antioxidant capacity of piceatannol is necessary or sufficient for its
antilipogenic/antiadipogenic properties. Regarding antioxidant capacity on its own, it has been
recently reported that piceatannol is ~10 times more effective than resveratrol in scavenging reactive
oxygen species [25]. Those impressive antioxidant properties of piceatannol might be the consequence
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of a more “equilibrated” molecule [26,27] since it possesses two hydroxyl groups on each of its two
phenolic cycles, while resveratrol contains only a total of three OH. We had previously reported that
piceatannol inhibits MAO activity [27], a mitochondrial enzyme that generates hydrogen peroxide and
which is highly expressed in human adipocytes [28], suggesting that piceatannol cannot be considered
as a mere antioxidant and reinforcing the idea that adipocytes might belong to the list of its targets.
Piceatannol’s delipidating properties have been gaining traction since it was reported to limit
fat accumulation in murine preadipocyte cell lines by two independent studies in 2012 [10,13].
Its anti-adipogenic action was later confirmed in the same model [11,12], and extended to the
LiSa-2 cells [13] derived from a human liposarcoma [29]. More recently, it has been reported that
piceatannol can also limit fat deposition in Caenorhabditis elegans [30] and in mice fed a high-fat
diet [31]. Additional reports have also been published on piceatannol’s ability to lower circulating
lipids in the spontaneously obese Zucker rats [11] and in high-fat diet fed Fisher rats [32], although
without reducing their body weight gain. Thus, piceatannol, structurally similar to resveratrol but
less studied for its anti-obesity actions, exhibits potential interest to limit the development of fat stores
in vivo. We conclude that piceatannol can act, among other targets, upon the adipocytes and their
precursors within fat depots. This in vitro study paves the way for further research to support whether
piceatannol supplementation in humans may function as a novel anti-obesity approach in the context
of an integrated weight loss or preventive strategy.
4. Materials and Methods
4.1. Patients and Human Adipose Tissue Samples
hMSC were obtained after collagenase digestion of subcutaneous abdominal fat from patients
undergoing bariatric surgery at the Hospital Universitario Miguel Servet (Zaragoza, Spain) following
a previously described protocol [33], which was approved by the Clinical Investigation Ethics
Committee of Aragon (ref #11/2013, approval date: 6 December 2013). A total of five donors were
selected from a cohort for their different body mass index (BMI), varying from 20 to >40. One was
excluded after the first preliminary tests for not fulfilling the criterion of apparent lack of metabolic
dysfunctions, as the excluded individual was inadvertently on antidiabetic medication.
Samples of human subcutaneous adipose tissue were obtained from five overweight women
undergoing reconstructive surgery at Rangueil Hospital (Toulouse, France) who gave their informed
consent for inclusion before they participated in the study. Their mean age was 43 years, and mean
body mass index was 25.6 ± 0.8 kg/m2. Biopsies were kept at −80 ◦C without any medium.
The study was in compliance with the INSERM guidelines and approved by the local ethic committee
(reference DC-2008-452)
4.2. Cell Cultures and Treatments
Cells were maintained at 37 ◦C in a humidified 5% CO2 atmosphere, and cultured until confluence
in DMEM (Lonza, Verviers, Belgium) containing 10% fetal bovine serum (FBS), 4 mM glutamine, 1 mM
sodium pyruvate, and 1% penicillin/streptomycin. The concentration of glucose for this growing
phase was 1 g/L for hMSC and 4.5 g/L for 3T3-L1 cells. Post-confluent differentiation of hMSC or
3T3-L1 was induced with DMEM 4.5 g/L glucose (Lonza, Verviers, Belgium) supplemented with
10% FBS, 1 µM dexamethasone, 0.5 mM isobutylmethylxanthine, 1 µM rosiglitazone, and 1.67 µM
human insulin. This medium was changed every 72 h until cells were differentiated in the case of
hMSC. In the case of 3T3-L1 preadipocytes the challenge to this differentiating medium lasted 2 days,
then the cells were changed to same medium with insulin only. Differentiating cells were grown in
6- or 12-well plates, and media supplemented with either vehicle (0.06% DMSO) or with piceatannol
(Selleckchem, Houston, TX, USA) at 50 µM final. Two protocols of treatment were performed for the
hMSC: one, named “pre-differentiation,” lasted one week with piceatannol, followed by one week
with high-glucose culture medium; while the other, named “post-differentiation,” consisted in one
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week with differentiation medium, followed by one week in high-glucose medium supplemented
with piceatannol.
At the end of treatments, several wells were used for cytotoxicity determination while in other
wells, supernatant was removed, and cells were used for triglyceride determination, RNA extraction,
or glucose uptake assays.
4.3. Assessment of Cell Viability, Lipid Accumulation, and Expression of Lipogenic Enzymes
Cell viability was assessed using the neutral red assay (TOX4 kit, Sigma-Aldrich, St. Louis, MO,
USA) following manufacturer’s recommendations.
The culture wells of hMSC or 3T3-L1 were fixed with 1 mL of 10% paraformaldehyde in PBS
for 15 min. Then, 400 µL of Oil Red O solution were added before microphotography with a Nikon
Eclipse TS100 microscope (Nikon Corporation, Tokyo, Japan). Lastly, the dye was extracted by 100%
isopropanol and optical density was quantified at 500 nm. Alternatively, Nile Red staining was
performed similarly save that fluorescence readouts were detected at 485/590 nm.
RNA samples were extracted from cells treated or not with piceatannol by using Trizol (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s instructions. The integrity of the RNA extracted
was verified using RNA 6000 Nano Assay (Thermo Scientific, Wilmington, DE, USA). RNA samples
were then treated with DNaseI kit (Applied Biosystems Inc., Foster City, CA, USA) to remove genomic
DNA. Reverse transcription was performed on 1 µg of total RNA, and relative mRNA levels of enzymes
involved in adipocyte differentiation and lipogenic pathways were quantified using real-time PCR
and the primer sequences as already described [34].
4.4. Glucose Transport and Incorporation into Lipids
When hMSC were considered as fully differentiated, two weeks after confluence, they were
incubated in 600 µL/well of KRPH medium (136 mM NaCl, 5 mM NaH2PO4, 4.7 mM KCl, 1 mM
MgSO4, 1 mM CaCl2 and 20 mM HEPES) during 90 min at 37 ◦C and 5% CO2, then treated without or
with insulin (0.5 µM) for additional 30 min. The addition of 0.30 µCi/well of [3H]-Deoxy–D-Glucose
(1 mCi/mL, #NET549250UC, Perkin-Elmer), for 10 min corresponded to the hexose uptake assay,
which was achieved by extensive washing with KRPH and by lysing the cells in 500 µL of 0.2 N NaOH
in 0.1% SDS at 4 ◦C. Aliquots of 300 µL were mixed with 2 mL of scintillation liquid (Ultima Gold,
PERKIN-ELMER #6013321), and the incorporated mixture was radioactivity counted in a 1209 Rackbeta
Liquid Scintillation Counter (LKB Wallac Co., Turku, Finland).
Incorporation of D-[3-3H]-glucose into lipids was assessed in mouse fat cells according to a recently
described protocol [35], then validated in [19]. To this aim, 14 C57Bl6 mice of both gender were
obtained from Charles River, L’arbresle, France), housed in plastic cages and sacrificed in accordance
with INSERM guidelines, to remove intra-abdominal fat pads and separate adipocytes as recently
reported [36]. Briefly, freshly isolated adipocytes were incubated at 37 ◦C in the same medium as
above, except that energy was provided by D-[3-3H]-glucose at 0.6 mM final concentration in vials that
were used for 120-min incubation and for lipid extraction by non-water miscible liquid scintillation
cocktail (InstaFluorPlus, PerkinElmer, Waltham, MA, USA). Then, only the radiolabelled glucose that
was incorporated in neo-synthesized radioactive lipids (organic phase) was counted in the same device
as for glucose uptake assay.
4.5. Hydrogen Peroxide Detection in Adipose Tissue Homogenates
Homogenates were prepared just prior assays from thawed hAT samples by using homogenizer
Tissue Master-125 (Omni International, Kennesaw, GA, USA) for approximately 40 sec. Using 50 µL
of homogenates distributed in 96-well black microplates, the chromogenic mixture was added to
reach 4 U/mL horseradish peroxidase and 40 µM 10-acetyl-3,7-dihydrophenoxazine in a final volume
of 200 µL of 200 mM phosphate buffer (pH 7.4). Hydrogen peroxide was measured owing to the
fluorescent probe as initially described by Zhou et al. for the continuous fluorometric determination of
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monoamine oxidase activity [37], with already reported minor adaptations [27]. Before the incubation
that lasted 30 min at 37 ◦C, the preparations were preincubated for 30 min alone or with piceatannol
at the indicated final concentrations. The fluorescent signal (ex/em: 540/590 nm) was collected in
a Fluoroskan Ascent plate reader (ThermoLabsystems, Helsinki, Finland), and the readouts after
30-min incubation were subtracted from corresponding values at time 0. Assay of hydrogen peroxide
from 0.05 to 5 µM was performed in parallel and used for standard curve as previously detailed [27].
4.6. Statistical Analysis
Experimental data in vitro were expressed as the means ± SEM of the indicated number of
experiments or replicates. We used Student’s t test for comparing two groups and one-way ANOVA,
followed of Dunnett’s test for multiple comparisons. All statistical analysis was performed using
Graph Pad Prism and R (v.3.0.3) software (https://cran.r-project.org/). The differences were deemed
to be statistically significant at p values < 0.05.
5. Conclusions
To conclude, our present work gives a clinical relevance for all these observations by reporting
for the first time the antiadipogenic effect and delipidating effect of piceatannol in human adipocytes
derived from stroma cells. Although limited to in vitro conditions and to piceatannol, our finding
indicate that the class of stilbenoids, and more widely many other phytoalexins known to act as
antimicrobial compounds in plants, can be useful to prevent or treat metabolic diseases in a manner
as—or even more—efficient than that of their parent molecule, resveratrol, which currently lacks
strong scientific support for being considered as a novel anti-obesity agent.
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